Jubilant Pharmova Ltd. Fundamental & Technical Research, Share Price Today

NSE : JUBLPHARMA
NIFTY : Nifty 500
NIFTY SECTOR : Nifty MidSmall Healthcare

About Company

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company with global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses. With a solid network of radio-pharmacies in the US, Jubilant’s Radiopharma business is engaged in manufacturing and supply of Radiopharmaceutical products and services. Its other businesses such as Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Generics (Solid Dosage Formulations) caters to major regulated markets (USA, EU and other geographies) through five manufacturing facilities. The CRDMO segment (through Jubilant Biosys) provides collaborative research and partnership for Drug Discovery through two world class research centers in India. The company is also involved in the manufacturing of Active Pharmaceutical Products (API) through a US FDA approved facility in Nanjangud, Karnataka.

Market Cap. ₹14,070 Cr.

52 Week - High/Low ₹1,310/608

P/E Ratio 368.06

P/B Ratio 5.93

Enterprise Value ₹14,324 Cr.

ROE % 1.32

RSI Value 45.13

EMA 50 935.74

EMA 200 936.78

Net Profit 32 Cr.

Net Profit 3year growth -85.27 Cr.

Net Profit 3 year (back) 214 Cr.

Debt to Equity 0.15 %

EPS Growth TTM -220.0 %

Current Ratio 1.71 %

100 Day SMA 1,010 Rs.

200 Day SMA 989 Rs.

21 Day SMA 896 Rs.

50 Day SMA 932 Rs.

Book Value 149 Rs.

EV/EBITDA Ratio 103

QoQ EPS Growth -50 %

QoQ Operating Profit Growth -280 %

QoQ Sales Growth 18 %

Sales Latest Quarter 193 Cr.

YoY Sales Growth 12 %

Market Cap. ₹14,070 Cr.

52 Week - High/Low ₹1,310/608

P/E Ratio 22.31

P/B Ratio 2.59

Enterprise Value ₹17,119 Cr.

ROE % 1.34

RSI Value 45.13

EMA 50 935.74

EMA 200 936.78

Net Profit 77 Cr.

Net Profit 3year growth 100.69 Cr.

Net Profit 3 year (back) 836 Cr.

Debt to Equity 0.63 %

EPS Growth TTM 1542.74 %

Current Ratio 1.92 %

100 Day SMA 1,010 Rs.

200 Day SMA 989 Rs.

21 Day SMA 896 Rs.

50 Day SMA 932 Rs.

Book Value 341 Rs.

EV/EBITDA Ratio 13

QoQ EPS Growth -2 %

QoQ Operating Profit Growth -3 %

QoQ Sales Growth 4 %

Sales Latest Quarter 1,814 Cr.

YoY Sales Growth 9 %

Add Parameters

Valuation

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages